iShares Biotechnology ETF

iShares·Tracks NYSE Biotechnology Index·Inception Feb 5, 2001

Expense ratio
0.44%
44.0 bps
Net assets
$10.47B
TTM yield
0.20%
Last price
$202.64
as of Sep 10, 2026

Composite score

70/ 100
Cost56

Based on a 0.44% expense ratio.

Liquidity100

Based on $10.47B in net assets.

Concentration37

Top-10 holdings represent 54.3% of net assets.

Tax efficiency85

Healthcare base · ETF wrapper · 0.20% TTM yield.

The composite is a weighted average of the four core sub-scores above (cost, tax efficiency, liquidity, concentration). Missing sub-scores fall back to the per-category median when the category has at least 50% data coverage, so funds without (e.g.) parsed N-PORT holdings aren't accidentally boosted by renormalization. Tracking quality is shown where computable but isn't currently part of the composite weighting. Seemethodologyfor formulas, thetracking-qualitypartial-coverage rationale, and the dimensions we deliberatelydon't score(methodology v0.5.1).

Use IBB in our tools

Top holdings

252 total holdings· as of Jun 30, 2026
#HoldingWeight
1BlackRock Funds III11.66%
2Vertex Pharmaceuticals, Inc.8.08%
3Amgen, Inc.7.83%
4Gilead Sciences, Inc.6.84%
5Regeneron Pharmaceuticals, Inc.4.91%
6Argenx SE3.76%
7Alnylam Pharmaceuticals, Inc.3.12%
8Natera, Inc.2.89%
9Revolution Medicines, Inc.2.78%
10Biogen, Inc.2.47%

Compare IBB with another fund

Or skim the closest-overlap funds below.

Similar ETFs by holdings overlap

Open IBB at a brokerage

Affiliate links — opening an account through these earns PlainIndex a one-time referral. Scoring is computed before any affiliate consideration; see our methodologyand funding disclosure.

Holdings sourced fromSEC Form N-PORT-P(accession 0002071691-26-019768).